



Miralles Andreu, G; Pomares Bernabeu, M; Gutierrez Palomo, S; Jiménez Pulido, IP; Soriano Irigaray, L; Navarro Ruiz A.
Hospital General Universitario de Elche, Pharmacy Department, Elche, Spain.

BACKGROUND AND IMPORTANCE

-  June 2019 → Risk of **reactivation due to hepatitis B virus (HBV)** in patients treated with **daratumumab**.
- Recommendation:** HBV screening in patients before daratumumab initiation and in ones already under treatment.
- Risk factors:**
 - ✓ Previous autologous stem cell (ASCT)
 - ✓ Concurrent and/or prior immunosuppressive therapy (IT)
 - ✓ Prevalence HBV regions



AIM AND OBJECTIVES

To analyse the level of compliance with the recommendations for the **prevention of HBV reactivation** and the risk in our hospital.

MATERIALS AND METHODS

- Descriptive retrospective observational study
- Patients treated with daratumumab since it was commercialized (January 2017 – September 2020)

Variables collected	
Sex	Age
Diagnosis	Daratumumab start date
VHB reactivation risk factors	Serology tests
HBV vaccination	HB infection

Information was collected from Abucasis®, Farmis® y Gestlab®.

RESULTS


- 20 patients included
- Median 70±17 years old
- 60% male

Main diagnosis:

- 95% multiple mieloma
- 5% amyloidosis

Risk factors for HBV reactivation:

- 20% received previous ASCT
- 90% treated with IT



CONCLUSION

- Only 65% of the patients have at least one HBV serology test.
- More serology tests should be carried out to detect risk patients.
- No HBV reactivations were detected at our hospital.